News &amp; Updates

The novel selective orexin-2 receptor (OX2R) antagonist seltorexant helped promote sleep in people with insomnia, with the efficacy maintained over a 2-week treatment period, according to a phase 2b study.

Novel selective OX2R antagonist works well for people with insomnia

Fenestrated outdoes conventional silicone stents in benign central airway stenosis

The use of fenestrated stents results in longer patency, fewer complications, and improved biomechanical performance than conventional silicone stents, without compromising the structural integrity of the stent, according to a study.

Fenestrated outdoes conventional silicone stents in benign central airway stenosis

Mizagliflozin improves postprandial glucose in postbariatric hypoglycaemia

Patients with postbariatric hypoglycaemia (PBH) may benefit from using mizagliflozin, which contributes to significant reductions in hypoglycaemic events, reports a study presented at ENDO 2025.

Mizagliflozin improves postprandial glucose in postbariatric hypoglycaemia

Setmelanotide lowers BMI in patients with hypothalamic obesity

Treatment with setmelanotide results in significant BMI reductions in individuals with acquired hypothalamic obesity compared with placebo, with an acceptable safety profile, as shown by the results of a phase III study presented at ENDO 2025.

Setmelanotide lowers BMI in patients with hypothalamic obesity

20 Aug 2025

CSP vs BVP: Which one is better for HFrEF with non-LBBB?

In a meta-analysis comparing procedural and clinical outcomes between conduction system pacing (CSP) and biventricular cardiac resynchronization pacing (BVP), the former appears to outdo the latter for managing individuals with heart failure with reduced ejection fraction (HFrEF) without left bundle branch block (LBBB).

CSP vs BVP: Which one is better for HFrEF with non-LBBB?

20 Aug 2025

Rivaroxaban curbs MACE, major bleeding risks in AF patients with CAD, regardless of age

Monotherapy with rivaroxaban in patients with atrial fibrillation (AF) and stable coronary artery disease (CAD) appears to protect against the risks of major adverse cardiovascular event (MACE) and major bleeding, with the benefit observed across the broad range of age, according to a post hoc analysis of the open-label AFIRE* trial.

Rivaroxaban curbs MACE, major bleeding risks in AF patients with CAD, regardless of age

Smoking cessation experts from New Zealand and Malaysia come together to give their thoughts on the recent vape issues.

Vape or e-cigarette is a rather recent arrival in the nicotine delivery route. As such, little is known about the long-term effects of vaping. However, developments in recent years have brought vaping to the limelight as it is becoming increasingly obvious that the vape industry is targeting youth. Initially unintentional, but increasingly deliberate as it became obvious that youth were a valuable source of current and future income.

Smoking cessation experts from New Zealand and Malaysia come together to give their thoughts on the recent vape issues.

Sintilimab plus axitinib shows therapeutic potential in FH-deficient RCC

The combination of sintilimab plus axitinib demonstrates encouraging antitumour activity in patients with fumarate hydratase–deficient renal cell carcinoma (FH-deficient RCC) while having a manageable safety profile, according to a phase II study conducted in China.

Sintilimab plus axitinib shows therapeutic potential in FH-deficient RCC

GLP-1 drugs can raise testosterone levels in men

19 Aug 2025 by

The use of glucagon-like peptide 1 (GLP-1) drugs such as semaglutide, dulaglutide, and the dual agonist tirzepatide helps boost testosterone levels in men with obesity and type 2 diabetes (T2D), according to new research.

GLP-1 drugs can raise testosterone levels in men

PMN-MDSCs tied to outcomes, antibiotic response in bronchiectasis

Polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) can set up an immunosuppressive microenvironment in the lung via arginase-1 (ARG-1) bronchiectasis, which is linked to clinical outcomes and response to antibiotic treatment among patients with bronchiectasis, suggests a study.

PMN-MDSCs tied to outcomes, antibiotic response in bronchiectasis